[go: up one dir, main page]

US20130171237A1 - Aripiprazole compositions and methods for its transdermal delivery - Google Patents

Aripiprazole compositions and methods for its transdermal delivery Download PDF

Info

Publication number
US20130171237A1
US20130171237A1 US13/668,500 US201213668500A US2013171237A1 US 20130171237 A1 US20130171237 A1 US 20130171237A1 US 201213668500 A US201213668500 A US 201213668500A US 2013171237 A1 US2013171237 A1 US 2013171237A1
Authority
US
United States
Prior art keywords
aripiprazole
pharmaceutical composition
composition
alcohol
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/668,500
Inventor
Fotios M. Plakogiannis
Anwar Muhammed Hossain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aequus Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/668,500 priority Critical patent/US20130171237A1/en
Assigned to ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC. reassignment ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLAKOGIANNIS, FOTIOS, HOSSAIN, MUHAMMED ANWAR
Publication of US20130171237A1 publication Critical patent/US20130171237A1/en
Assigned to TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC reassignment TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC.
Assigned to TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC. reassignment TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC.
Assigned to AEQUUS PHARMACEUTICALS, INC. reassignment AEQUUS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the field of transdermal delivery of pharmaceutical compositions, which have an acceptable in vitro performance and good bioavailability.
  • the transdermal pharmaceutical compositions of the present invention include liquids or gels of aripiprazole in a patch dosage form.
  • ARPZ Aripiprazole
  • 3-4 ARPZ is a quinolinone derivative, white crystalline powder, practically insoluble in water, with a low melting point (135-140° C.), MW 448.38 g/mole and partition coefficient of 4.54.
  • the invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising: aripiprazole in the amount of about 1 to 20% w/v; a gelling agent in the range of about 0.1% to 5% w/v; an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; wherein the pH of the composition is maintained at approximately 6 to 7.
  • the invention further provides a composition of the invention wherein the gelling agent is poloxamer.
  • the invention further provides a composition of the invention wherein the form is a patch for transdermal delivery.
  • the invention further provides a composition of the invention wherein the dosage form is an ointment, cream, emulsion, or liposome.
  • the invention further provides a composition of the invention further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water.
  • the invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
  • the invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising: aripiprazole present in the amount of 1 to 20% w/v; an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof, an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; wherein the pH of the composition is maintained at approximately 6 to 7.
  • the invention further provides a composition of the invention wherein the form is a patch for transdermal delivery.
  • the invention further provides a composition of the invention being in the dosage form of an ointment, cream, emulsion, or liposome.
  • the invention further provides a composition of the invention further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water.
  • the invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
  • the invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising: aripiprazole in the amount of about 1 to 20% w/v; a gelling agent in the range of about 0.1% to 5% w/v; an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; about 40% N-methyl-2-pyrrolidone, 40% dimethylsulfoxide, 15% alcohol and 5% water; wherein the pH of the composition is maintained at approximately 6 to 7.
  • the invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations
  • the invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising: aripiprazole present in the amount of 1 to 20% w/v; an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof, an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol and about 5% water; wherein the pH of the composition is maintained at approximately 6 to 7.
  • the invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myr
  • the invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%.
  • the invention further provides a composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7.
  • the invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%.
  • the invention further provides a composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7.
  • the invention provides that the pH of the composition is maintained at approximately 6 to 7 using HC1.
  • the invention provides that the pH of the composition is maintained at approximately 6 to 7 using at least one buffer.
  • FIG. 1 is a graph showing Effect of Drug Concentration on the Flux of ARPZ through Cellulose Membrane from 0.5% CARBOPOL® 971 Gel Systems.
  • FIG. 2 is a graph showing Cumulative Amount of 5% ARPZ Permeated through Cadaver Skin from 0.5% CARBOPOL® Gel System
  • FIG. 3 is a graph showing Cumulative Amount of Drug Permeated through Human Cadaver Skin from 5% ARPZ in 0.5% CARBOPOL® Gel Systems with Enhancers (Fatty Acids)
  • the invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery.
  • the invention provides a pharmaceutical composition of the invention wherein the aripiprazole is in a gel or liquid form.
  • the invention provides a pharmaceutical composition of the invention wherein the aripiprazole is present in the amount of 1 to 20% w/v.
  • the invention provides a pharmaceutical composition of the invention wherein the aripiprazole is present in the amount of 1 to 20% w/v.
  • the invention provides a pharmaceutical composition of the invention wherein the gel contains a gelling agent in the range of about 0.1% to 5% w/v.
  • the invention provides a pharmaceutical composition of the invention further comprising approximately 40% N-methyl-2-pyrrolidone, 40% Dimethylsulfoxide, 15% alcohol and 5% water.
  • the invention provides a pharmaceutical composition for transdermal delivery which comprises ARPZ 2%; DMSO at a concentration of about 10 to 40%, and at a preferred concentration of about 25%; NMP at a concentration of about 5 to 40%, and a preferred concentration is about 10%; Isopropyl alcohol (IPA) at a concentration of about 1 to 15%, and a preferred concentration is about 5%; Ethyl Alcohol at a concentration of about 15 to 40%, and a preferred concentration is about 40%; PEG 400 at a concentration of about 1 to 15%, and a preferred concentration is about 15%; CARBOPOL® 971P at a concentration of about 0.25 to 5%, and a preferred concentration is about 0.5%; and water, q.s. to 100%.
  • ARPZ 2% DMSO at a concentration of about 10 to 40%, and at a preferred concentration of about 25%
  • NMP at a concentration of about 5 to 40%, and a preferred concentration is about 10%
  • Isopropyl alcohol (IPA) at a concentration of about 1 to 15%,
  • the invention provides a pharmaceutical composition of the invention being in the form of a liquid and comprising an alcohol, glycol, mineral oil, and/or vegetable oil.
  • the invention provides a pharmaceutical composition of the invention wherein the composition is in a gel form and further comprises a gelling agent selected from the group consisting of natural polymers, semisynthetic polymers, synthetic polymers, carboxyvinyl polymers or carbomers, CARBOPOL® 940, CARBOPOL® 934, CARBOPOL® 971, poloxamer, polyacrylamide, polyvinyl alcohol, polyethylene and co-polymers thereof.
  • the invention provides a pharmaceutical composition of the invention wherein the form is a patch for transdermal delivery.
  • the invention provides a pharmaceutical composition of the invention being in the dosage form of an ointment, cream, emulsion, or liposome.
  • the invention provides a pharmaceutical composition of the invention wherein the aripiprazole is present in the amount of 1 to 20% w/v.
  • the invention provides a pharmaceutical composition of the invention further comprising an enhancer.
  • the invention provides a pharmaceutical composition of the invention wherein the enhancer is selected from the group consisting of lauric acid, myristc acid, water, sulfoxides, dimethylsulfoxide, dimethylacetamide, dimethylformamide, decymethylsulfoxide, pyrrolidones, fatty acid esters, fatty acids, alcohols, fatty alcohols and glycols, urea, essential oils, terpene and terpenoids, liposomes, niosomes, transferomes and ethanosomes.
  • the invention provides a pharmaceutical composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7.
  • the invention provides a pharmaceutical composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7.
  • ARPZ is practically insoluble in water and has been formulated as a liquid and gel dosage form (Table 1). All reported values are in weight/volume percentage (W/V)
  • the optimum composition of a 1% W/V to 20% W/V ARPZ liquid formulation was predicted to have NMP 40%, DMSO 40%, Alcohol 15% and water 5% (Table 1).
  • the gel formulation should contain a gelling agent in the range of about 0.1% to 5% W/V and the optimum APRZ composition should range from about 1% W/V to 20% W/V with about 0.5% W/V of the gelling agent. Therefore, the gel formulation was predicted to have a NMP of 40%, DMSO 40%, Alcohol 15%, CARBOPOL® 971 0.5%, and Water 4.5% (Table 1).
  • Table 2 lists other combinations that also could produce successful liquid and gel ARPZ formulations in accordance with the present invention.
  • NMP N-Methyl-2-Pyrolidone
  • DMSO Dimethl Sulfoxide
  • Ethyl Alcohol Water in Liquid Aripiprazole Formulation Formulation NMP DMSO Alcohol Water 1. 50 50 — — 2. 40 40 20 — 3. 40 40 — 20 4. 40 40 15 5 5. 40 40 10 10 6. 40 40 5 15 7. 30 30 20 20 8. 30 30 30 10 9. 30 40 25 5 10. 40 30 25 5 11. 45 45 10 0 12. 45 40 10 5
  • solvents known to those skilled in the art suitable for use in the present invention can be used to prepare the liquid formulation, and combinations thereof, including but not limited to alcohols such as but not limited to (methyl, ethyl, butyl, propyl, isopropyl, isopropyl myristate, etc.), glycols such as, but not limited to (propylene, polyethylene, glycerin, etc.) mineral oils, vegetable oils, and others.
  • the optimal desired composition of ARPZ gel formulation contains 0.5% W/V CARBOPOL® 971.
  • ARPZ can be gelled by gelling agents, including but not limited to, natural polymers (such as agar, alginic acid and derivatives, cassia tora, collagen, gelatin, gellum gum, guar gum, pectin, potassium, or sodium carageenan, tragacanth, xanthan, etc.), semisynthetic polymers (such as methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, etc.) synthetic polymers (such as carboxyvinyl polymers or carbomers: CARBOPOL® 940, CARBOPOL® 934, CARBOPOL® 971, poloxamer, polyacrylamide, polyvinyl alcohol, polyethylene, and its co-polymers etc), and clays (such as silicates, etc).
  • natural polymers such as agar, alginic acid and derivatives, cassia tora, collagen, gelatin, gellum gum, guar gum, pectin, potassium,
  • ARPZ can be evaluated with other artificial membranes including but not limited to silicone membranes (polydimethylsiloxane), liposome-coated membranes, solid-supported liquid membranes, lecithin organogel membranes and other.
  • other dosage forms including, but not limited to, ointments, creams, emulsions, liposomes, etc. may be used.
  • the effect of enhancers on the flux of ARPZ through human cadaver skin was evaluated and is shown in FIG. 3 .
  • the desired optimum composition of ARPZ gel formulation contained Lauric and Myristc acid.
  • the ARPZ transdermal delivery can be influenced by enhancers including but not limited to water, sulfoxides, and similar chemicals, dimethylsulfoxide (DMSO), dimethylacetamide (DMAC), dimethylformamide (DMF), decymethylsulfoxide (DCMS) etc, pyrrolidones N-methyl-2-pyrrolidone (NMP), 2-pyrrolidon (2p), etc., fatty acids esters (butyl ethanoate, ethyl ethanoate, ethyl oleate, isopropyl myristate, isopropyl palmiate, methyl ethanoate etc), fatty acids (capric, caprylic, lauric, oleic, my
  • the effects of pH on the permeation of ARPZ through human cadaver skin were evaluated and a characteristic graph is shown in FIG. 2 .
  • the preferred optimum composition of ARPZ gel transdermal formulation had a pH in the range of approximately 6 to 7.
  • the ARPZ transdermal delivery may be influenced by pH values outside of the preferred range, but to a lesser extent.
  • the present invention may still be achieved outside of the preferred pH range of approximately 6 to 7, depending upon the circumstances of use.
  • the systems of this discovery can deliver ARPZ at a flux between 50 mcg/ch-2. h and 800 mcg/ch-2.h, which can produce the required therapeutic ARPZ blood levels.
  • Flux rate can be changed by modifying such parameters as ARPZ initial concentration, surface area of the patch, pH of the formulation, vehicle composition, enhancer type and composition, etc., in accordance with the teachings of the present invention.
  • Optimum therapeutic outcome requires not only a proper drug selection but also an effective drug delivery.
  • Psychotropic drug compliance of rigorous regular medication schedules is of great importance.
  • oral administration of psychotropic agents is considered a less than optimal delivery system due to patient non-compliance 5 .
  • Transdermal delivery of psychotropic drugs, especially with prolonged duration of action, would be valuable in increasing medication compliance, especially in the geriatric population.
  • potential advantages of ARPZ transdermal delivery are as follows: lack of hepatic first pass effect; eliminating the potential for over- or under-dosing; allowing the flexibility of terminating the drug administration by simply removing the patch; providing a simplified therapeutic regimen, thereby assisting medication compliance in the geriatric population.
  • a transdermal composition of Aripiprazole is shown below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Secondary Cells (AREA)

Abstract

The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation in part of PCT/US2011/057080 filed Oct. 20, 2011, which claims benefit of U.S. Provisional Patent Application Ser. No. 61/407,591 filed Oct. 28, 2010.
    • BACKGROUND OF THE INVENTION
  • 1. Field of Invention
  • The present invention relates to the field of transdermal delivery of pharmaceutical compositions, which have an acceptable in vitro performance and good bioavailability. In particular, the transdermal pharmaceutical compositions of the present invention include liquids or gels of aripiprazole in a patch dosage form.
  • 2. Background of Invention
  • Aripiprazole (ARPZ) is the first of a new class of atypical antipsychotics (third generation). Biochemically, ARPZ is a partial agonist of the D2 family of dopamine receptors.1,2 It is active against positive and negative symptoms of schizophrenia.3,4 ARPZ is a quinolinone derivative, white crystalline powder, practically insoluble in water, with a low melting point (135-140° C.), MW 448.38 g/mole and partition coefficient of 4.54.
  • All references cited herein are incorporated herein by reference in their entireties.
    • BRIEF SUMMARY OF THE INVENTION
  • The invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising: aripiprazole in the amount of about 1 to 20% w/v; a gelling agent in the range of about 0.1% to 5% w/v; an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; wherein the pH of the composition is maintained at approximately 6 to 7. The invention further provides a composition of the invention wherein the gelling agent is poloxamer. The invention further provides a composition of the invention wherein the form is a patch for transdermal delivery. The invention further provides a composition of the invention wherein the dosage form is an ointment, cream, emulsion, or liposome. The invention further provides a composition of the invention further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water. The invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
  • The invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising: aripiprazole present in the amount of 1 to 20% w/v; an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof, an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; wherein the pH of the composition is maintained at approximately 6 to 7. The invention further provides a composition of the invention wherein the form is a patch for transdermal delivery. The invention further provides a composition of the invention being in the dosage form of an ointment, cream, emulsion, or liposome. The invention further provides a composition of the invention further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water. The invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
  • The invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising: aripiprazole in the amount of about 1 to 20% w/v; a gelling agent in the range of about 0.1% to 5% w/v; an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; about 40% N-methyl-2-pyrrolidone, 40% dimethylsulfoxide, 15% alcohol and 5% water; wherein the pH of the composition is maintained at approximately 6 to 7. The invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
  • The invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising: aripiprazole present in the amount of 1 to 20% w/v; an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof, an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof; about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol and about 5% water; wherein the pH of the composition is maintained at approximately 6 to 7. The invention further provides a composition of the invention further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
  • The invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%. The invention further provides a composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7.
  • The invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%. The invention further provides a composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7. The invention provides that the pH of the composition is maintained at approximately 6 to 7 using HC1. The invention provides that the pH of the composition is maintained at approximately 6 to 7 using at least one buffer.
    • BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS
  • The invention will be described in conjunction with the following wherein:
  • FIG. 1 is a graph showing Effect of Drug Concentration on the Flux of ARPZ through Cellulose Membrane from 0.5% CARBOPOL® 971 Gel Systems.
  • FIG. 2 is a graph showing Cumulative Amount of 5% ARPZ Permeated through Cadaver Skin from 0.5% CARBOPOL® Gel System
  • FIG. 3 is a graph showing Cumulative Amount of Drug Permeated through Human Cadaver Skin from 5% ARPZ in 0.5% CARBOPOL® Gel Systems with Enhancers (Fatty Acids)
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The invention provides a pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery. The invention provides a pharmaceutical composition of the invention wherein the aripiprazole is in a gel or liquid form. The invention provides a pharmaceutical composition of the invention wherein the aripiprazole is present in the amount of 1 to 20% w/v. The invention provides a pharmaceutical composition of the invention wherein the aripiprazole is present in the amount of 1 to 20% w/v. The invention provides a pharmaceutical composition of the invention wherein the gel contains a gelling agent in the range of about 0.1% to 5% w/v. The invention provides a pharmaceutical composition of the invention further comprising approximately 40% N-methyl-2-pyrrolidone, 40% Dimethylsulfoxide, 15% alcohol and 5% water.
  • The invention provides a pharmaceutical composition for transdermal delivery which comprises ARPZ 2%; DMSO at a concentration of about 10 to 40%, and at a preferred concentration of about 25%; NMP at a concentration of about 5 to 40%, and a preferred concentration is about 10%; Isopropyl alcohol (IPA) at a concentration of about 1 to 15%, and a preferred concentration is about 5%; Ethyl Alcohol at a concentration of about 15 to 40%, and a preferred concentration is about 40%; PEG 400 at a concentration of about 1 to 15%, and a preferred concentration is about 15%; CARBOPOL® 971P at a concentration of about 0.25 to 5%, and a preferred concentration is about 0.5%; and water, q.s. to 100%.
  • The invention provides a pharmaceutical composition of the invention being in the form of a liquid and comprising an alcohol, glycol, mineral oil, and/or vegetable oil. The invention provides a pharmaceutical composition of the invention wherein the composition is in a gel form and further comprises a gelling agent selected from the group consisting of natural polymers, semisynthetic polymers, synthetic polymers, carboxyvinyl polymers or carbomers, CARBOPOL® 940, CARBOPOL® 934, CARBOPOL® 971, poloxamer, polyacrylamide, polyvinyl alcohol, polyethylene and co-polymers thereof. The invention provides a pharmaceutical composition of the invention wherein the form is a patch for transdermal delivery. The invention provides a pharmaceutical composition of the invention being in the dosage form of an ointment, cream, emulsion, or liposome. The invention provides a pharmaceutical composition of the invention wherein the aripiprazole is present in the amount of 1 to 20% w/v.
  • The invention provides a pharmaceutical composition of the invention further comprising an enhancer. The invention provides a pharmaceutical composition of the invention wherein the enhancer is selected from the group consisting of lauric acid, myristc acid, water, sulfoxides, dimethylsulfoxide, dimethylacetamide, dimethylformamide, decymethylsulfoxide, pyrrolidones, fatty acid esters, fatty acids, alcohols, fatty alcohols and glycols, urea, essential oils, terpene and terpenoids, liposomes, niosomes, transferomes and ethanosomes.
  • The invention provides a pharmaceutical composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7. The invention provides a pharmaceutical composition of the invention wherein the pH of the composition is maintained at approximately 6 to 7.
  • The invention will be illustrated in more detail with reference to the following Examples, but it should be understood that the present invention is not deemed to be limited thereto.
    • EXAMPLES Example 1
  • ARPZ is practically insoluble in water and has been formulated as a liquid and gel dosage form (Table 1). All reported values are in weight/volume percentage (W/V)
  • TABLE 1
    Composition of liquid and gel formulation of Aripiprazole (5% W/V)
    W/V W/V
    N-methyl-2-pyrolidone (NMP) 40% 40%
    Dimethyl Sulfoxide (DMSO) 40% 40%
    Ethyl Alcohol
    15% 15%
    Carbopol 971P — 0.5% 
    Water  5% 4.5% 
    Total 100.00%    100.00%   
  • An optimal mixture design of experiments was used to select the levels of the formulation variables. The optimum composition of a 1% W/V to 20% W/V ARPZ liquid formulation was predicted to have NMP 40%, DMSO 40%, Alcohol 15% and water 5% (Table 1). The gel formulation should contain a gelling agent in the range of about 0.1% to 5% W/V and the optimum APRZ composition should range from about 1% W/V to 20% W/V with about 0.5% W/V of the gelling agent. Therefore, the gel formulation was predicted to have a NMP of 40%, DMSO 40%, Alcohol 15%, CARBOPOL® 971 0.5%, and Water 4.5% (Table 1). However, Table 2 lists other combinations that also could produce successful liquid and gel ARPZ formulations in accordance with the present invention.
  • TABLE 2
    Concentration Ranges of N-Methyl-2-Pyrolidone (NMP),
    Dimethl Sulfoxide (DMSO), Ethyl Alcohol, and Water in
    Liquid Aripiprazole Formulation
    Formulation NMP DMSO Alcohol Water
    1. 50 50 — —
    2. 40 40 20 —
    3. 40 40 — 20
    4. 40 40 15 5
    5. 40 40 10 10
    6. 40 40 5 15
    7. 30 30 20 20
    8. 30 30 30 10
    9. 30 40 25 5
    10. 40 30 25 5
    11. 45 45 10 0
    12. 45 40 10 5
  • Other than these components, other solvents known to those skilled in the art suitable for use in the present invention can be used to prepare the liquid formulation, and combinations thereof, including but not limited to alcohols such as but not limited to (methyl, ethyl, butyl, propyl, isopropyl, isopropyl myristate, etc.), glycols such as, but not limited to (propylene, polyethylene, glycerin, etc.) mineral oils, vegetable oils, and others.
    • Example 2
  • The effect of gelling agents and their concentration on the permeation of ARPZ through artificial membranes and human cadaver skin was evaluated and two characteristic graphs are shown in FIGS. 1 & 2. The optimal desired composition of ARPZ gel formulation contains 0.5% W/V CARBOPOL® 971. ARPZ can be gelled by gelling agents, including but not limited to, natural polymers (such as agar, alginic acid and derivatives, cassia tora, collagen, gelatin, gellum gum, guar gum, pectin, potassium, or sodium carageenan, tragacanth, xanthan, etc.), semisynthetic polymers (such as methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, etc.) synthetic polymers (such as carboxyvinyl polymers or carbomers: CARBOPOL® 940, CARBOPOL® 934, CARBOPOL® 971, poloxamer, polyacrylamide, polyvinyl alcohol, polyethylene, and its co-polymers etc), and clays (such as silicates, etc). In addition, other than cellulose membranes, ARPZ can be evaluated with other artificial membranes including but not limited to silicone membranes (polydimethylsiloxane), liposome-coated membranes, solid-supported liquid membranes, lecithin organogel membranes and other. Besides the gel formulations of ARPZ, other dosage forms including, but not limited to, ointments, creams, emulsions, liposomes, etc. may be used.
    • Example 3
  • The effect of enhancers on the flux of ARPZ through human cadaver skin was evaluated and is shown in FIG. 3. The desired optimum composition of ARPZ gel formulation contained Lauric and Myristc acid. Apart from Lauric and Myristc acid enhancer, the ARPZ transdermal delivery can be influenced by enhancers including but not limited to water, sulfoxides, and similar chemicals, dimethylsulfoxide (DMSO), dimethylacetamide (DMAC), dimethylformamide (DMF), decymethylsulfoxide (DCMS) etc, pyrrolidones N-methyl-2-pyrrolidone (NMP), 2-pyrrolidon (2p), etc., fatty acids esters (butyl ethanoate, ethyl ethanoate, ethyl oleate, isopropyl myristate, isopropyl palmiate, methyl ethanoate etc), fatty acids (capric, caprylic, lauric, oleic, myristic, linoleic, stearic, palmitic etc), alcohols, fatty alcohols and glycols (nathanol, dodecanol, propylene glycols, glycerol etc), urea, essential oils, terpene and terpenoids (limonene, thymol, cineole etc), liposomes, niosomes, transferomes, ethanosomes etc.
    • Example 4
  • The effects of pH on the permeation of ARPZ through human cadaver skin were evaluated and a characteristic graph is shown in FIG. 2. The preferred optimum composition of ARPZ gel transdermal formulation had a pH in the range of approximately 6 to 7. Other than these optimal pH values, the ARPZ transdermal delivery may be influenced by pH values outside of the preferred range, but to a lesser extent. Thus, the present invention may still be achieved outside of the preferred pH range of approximately 6 to 7, depending upon the circumstances of use.
  • The systems of this discovery can deliver ARPZ at a flux between 50 mcg/ch-2. h and 800 mcg/ch-2.h, which can produce the required therapeutic ARPZ blood levels. Flux rate can be changed by modifying such parameters as ARPZ initial concentration, surface area of the patch, pH of the formulation, vehicle composition, enhancer type and composition, etc., in accordance with the teachings of the present invention.
  • Optimum therapeutic outcome requires not only a proper drug selection but also an effective drug delivery. Psychotropic drug compliance of rigorous regular medication schedules is of great importance. In many instances, oral administration of psychotropic agents is considered a less than optimal delivery system due to patient non-compliance5. Transdermal delivery of psychotropic drugs, especially with prolonged duration of action, would be valuable in increasing medication compliance, especially in the geriatric population. Further, potential advantages of ARPZ transdermal delivery are as follows: lack of hepatic first pass effect; eliminating the potential for over- or under-dosing; allowing the flexibility of terminating the drug administration by simply removing the patch; providing a simplified therapeutic regimen, thereby assisting medication compliance in the geriatric population.
    • Example 5
  • A transdermal composition of Aripiprazole is shown below:
  •
    ARPZ  2%
    DMSO
    25%
    NMP
    10%
    Isopropylalcohol (IPA)  5%
    Ethyl Alcohol
    40%
    PEG
    400 15%
    Carbopol 971P 0.5% 
    HCl q.s. to pH 6-7
    WATER q.s. to 100%
  • While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
    • REFERENCES
    • 1. Inoue, T., Domae, M., Yamada, K., and Furukawa, T. Effects of the novel antipsychotic agent 7-([4-2,3-dichlorophenylo-1-piperazinyl]b Neuroutyloxyo-3,4-dihydro2 (1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary. J. Pharmacol. Exp. Ther. 1996; 277(1):137-143.
    • 2. Burris, K. D., Moiski, T. F., Ryan, E., Xu, C., Tottori, K., Kikuchi, T., Yocca, F. D, and Molinoff, P. B. Aripiprazole is a high affinity partial agonist at human D2 dopamine receptors. Int. J. Neuropsychopharmacol. 2000; 3(Suppl. 1), S129.
    • 3. Petrie, J. L., Saha, A. R., and McEvoy, J. P. Aripiprazole, a new atypical antipsychotic: Phase II clinical trial results. Eur. Neuropsychopharm 1997; 7 (Suppl 2): 5227.
    • 4. Saha, A. R., McQuade, R., Carson, W. H., Ali, M., W., Durbar, G. C., and Ingenito, G. Efficacy and safety of Aripiprazole and Risperidone vs. Placebo in patients with schizophrenia and schizoaffective disorder. World J. Biol Psych 2001; 2 (Suppl 1): 305S.
    • 5. Geeta, A., Sanju, D., Psychotropic Drugs and Transdermal Delivery. An Overview. Int. J. of Pharma and Bio Science, 2001; V 1(2).

Claims (19)

What is claimed is:
1. A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising:
aripiprazole in the amount of about 1 to 20% w/v;
a gelling agent in the range of about 0.1% to 5% w/v;
an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;
wherein the pH of the composition is maintained at approximately 6 to 7.
2. The pharmaceutical composition of claim 1 wherein the gelling agent is poloxamer.
3. The pharmaceutical composition of claim 1 wherein the form is a patch for transdermal delivery.
4. The pharmaceutical composition of claim 1 wherein the dosage form is an ointment, cream, emulsion, or liposome.
5. The pharmaceutical composition of claim 1 further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water.
6. The pharmaceutical composition of claim 5, further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
7. A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising:
aripiprazole present in the amount of 1 to 20% w/v;
an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof,
an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;
wherein the pH of the composition is maintained at approximately 6 to 7.
8. The pharmaceutical composition of claim 7 wherein the form is a patch for transdermal delivery.
9. The pharmaceutical composition of claim 7 being in the dosage form of an ointment, cream, emulsion, or liposome.
10. The pharmaceutical composition of claim 7 further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water.
11. The pharmaceutical composition of claim 10, further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
12. A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising:
aripiprazole in the amount of about 1 to 20% w/v;
a gelling agent in the range of about 0.1% to 5% w/v;
an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;
about 40% N-methyl-2-pyrrolidone, 40% dimethylsulfoxide, 15% alcohol and 5% water;
wherein the pH of the composition is maintained at approximately 6 to 7.
13. The pharmaceutical composition of claim 12, further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
14. A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising:
aripiprazole present in the amount of 1 to 20% w/v;
an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof,
an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;
about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol and about 5% water;
wherein the pH of the composition is maintained at approximately 6 to 7.
15. The pharmaceutical composition of claim 14, further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof.
16. A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%.
17. The pharmaceutical composition of claim 16, wherein the pH of the composition is maintained at approximately 6 to 7.
18. A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%.
19. The pharmaceutical composition of claim 18, wherein the pH of the composition is maintained at approximately 6 to 7.
US13/668,500 2010-10-28 2012-11-05 Aripiprazole compositions and methods for its transdermal delivery Abandoned US20130171237A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/668,500 US20130171237A1 (en) 2010-10-28 2012-11-05 Aripiprazole compositions and methods for its transdermal delivery

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40759110P 2010-10-28 2010-10-28
PCT/US2011/057080 WO2012058091A2 (en) 2010-10-28 2011-10-20 Aripiprazole compositions and methods for its transdermal delivery
US13/668,500 US20130171237A1 (en) 2010-10-28 2012-11-05 Aripiprazole compositions and methods for its transdermal delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/057080 Continuation-In-Part WO2012058091A2 (en) 2010-10-28 2011-10-20 Aripiprazole compositions and methods for its transdermal delivery

Publications (1)

Publication Number Publication Date
US20130171237A1 true US20130171237A1 (en) 2013-07-04

Family

ID=45994667

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/879,485 Active 2032-01-19 US9138402B2 (en) 2010-10-28 2011-10-20 Aripiprazole compositions and methods for its transdermal delivery
US13/668,500 Abandoned US20130171237A1 (en) 2010-10-28 2012-11-05 Aripiprazole compositions and methods for its transdermal delivery

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/879,485 Active 2032-01-19 US9138402B2 (en) 2010-10-28 2011-10-20 Aripiprazole compositions and methods for its transdermal delivery

Country Status (11)

Country Link
US (2) US9138402B2 (en)
EP (1) EP2632463B1 (en)
JP (2) JP5966228B2 (en)
CN (2) CN107929239B (en)
AU (1) AU2011320758B2 (en)
BR (1) BR112013010190B1 (en)
CA (1) CA2816203C (en)
ES (1) ES2675913T3 (en)
MX (1) MX339196B (en)
RU (1) RU2589689C2 (en)
WO (1) WO2012058091A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172344A1 (en) * 2013-04-16 2014-10-23 Alpha To Omega Pharmaceutical Consultants, Inc. Pharmaceutical compositions
EP3233077A1 (en) 2014-12-19 2017-10-25 The Broad Institute Inc. Dopamine d2 receptor ligands
US9913840B2 (en) 2015-06-08 2018-03-13 Corium International, Inc. Formulations for aripiprazole delivery transdermally

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
US10356018B2 (en) 2014-01-31 2019-07-16 Vivint, Inc. User management methods and systems
WO2017025912A1 (en) * 2015-08-13 2017-02-16 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
MA44779A (en) * 2016-04-25 2019-03-06 Otsuka Pharma Co Ltd COMPOSITIONS OF A PHARMACEUTICAL PRODUCT INCLUDING AN INGERABLE EVENT MARKER
JP6625208B2 (en) * 2016-05-12 2019-12-25 富士フイルム株式会社 Transdermal formulation
JPWO2018117125A1 (en) * 2016-12-19 2019-08-08 富士フイルム株式会社 Transdermal formulation

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US6579581B2 (en) * 2000-06-23 2003-06-17 Degussa Ag Polymer blend having good low-temperature impact strength
US20040170672A1 (en) * 2001-03-07 2004-09-02 Thorsten Selzer Transdermal therapeutic system for administration of partial dopamine-d2 agonists
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US7807680B2 (en) * 2003-10-23 2010-10-05 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
US20130041004A1 (en) * 2008-09-25 2013-02-14 Anthony S. Drager Liquid Formulations Of Bendamustine
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20130096073A1 (en) * 2000-03-01 2013-04-18 Zvi Sidelman Casein Derived Peptides And Uses Thereof
US8461129B2 (en) * 2006-09-25 2013-06-11 Archer Daniels Midland Company Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
US8815261B2 (en) * 2009-06-19 2014-08-26 Medrx Co., Ltd. Composition for external application comprising aripiprazole and organic acid as active ingredients
US20160058809A1 (en) * 2011-10-25 2016-03-03 U.S. Phytotherapy, Inc. Additional Artemisinin and Berberine Compositions and Methods of Making
US20160183518A1 (en) * 2014-12-31 2016-06-30 Valent U.S.A., Corporation Lactofen and dicamba diglycol amine liquid formulations
US20160256626A9 (en) * 2014-03-25 2016-09-08 Surefire Medical, Inc. Closed Tip Dynamic Microvalve Protection Device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101492A0 (en) 1992-04-03 1992-12-30 Shalom Levy Anti-skin rash preparation
US5616602A (en) * 1993-07-09 1997-04-01 Ciba-Geigy Corporation Topically administrable zinc phthalocyanine compositions
DE59509232D1 (en) * 1994-02-18 2001-06-13 Drossapharm Ag Basel Transdermal therapeutic system
DE10110953A1 (en) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermal therapeutic system for the administration of partial dopamine D2 agonists
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
JP5546717B2 (en) 2003-12-16 2014-07-09 テバ ファーマシューティカル インダストリーズ リミティド Method for preparing aripiprazole crystalline form
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
KR20090094811A (en) * 2006-10-05 2009-09-08 파나세아 바이오테크 리미티드 Novel injectable depot compositions and process of preparation of such compositions
GB0905365D0 (en) * 2009-03-27 2009-05-13 Norbrook Lab Ltd A topical parasiticide composition
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US20130096073A1 (en) * 2000-03-01 2013-04-18 Zvi Sidelman Casein Derived Peptides And Uses Thereof
US6579581B2 (en) * 2000-06-23 2003-06-17 Degussa Ag Polymer blend having good low-temperature impact strength
US20040170672A1 (en) * 2001-03-07 2004-09-02 Thorsten Selzer Transdermal therapeutic system for administration of partial dopamine-d2 agonists
US7807680B2 (en) * 2003-10-23 2010-10-05 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US8461129B2 (en) * 2006-09-25 2013-06-11 Archer Daniels Midland Company Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20130041004A1 (en) * 2008-09-25 2013-02-14 Anthony S. Drager Liquid Formulations Of Bendamustine
US8815261B2 (en) * 2009-06-19 2014-08-26 Medrx Co., Ltd. Composition for external application comprising aripiprazole and organic acid as active ingredients
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20160058809A1 (en) * 2011-10-25 2016-03-03 U.S. Phytotherapy, Inc. Additional Artemisinin and Berberine Compositions and Methods of Making
US20160256626A9 (en) * 2014-03-25 2016-09-08 Surefire Medical, Inc. Closed Tip Dynamic Microvalve Protection Device
US20160183518A1 (en) * 2014-12-31 2016-06-30 Valent U.S.A., Corporation Lactofen and dicamba diglycol amine liquid formulations

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Baranda, L. et al. "Correlation between pH and irritant effect of cleansers marketed for dry skin" Int. J. Derm. 2002, 41, 494-499 *
Bhattacharjee, H.; Thoma, L. "Parenteral drug administration: routes of administration and devices" Pharmaceutical Dosage Forms: Parenteral Medications, Third Edition, Chapter 2, August 2010, pgs 7-29 *
Lubrizol. TDS-730 "Viscosity of Carbopol Polymers in Aqueous Systems" Published 24 November 2009. (https://www.lubrizol.com/Life-Science/Documents/Pharmaceutical/Technical-Data-Sheets/TDS-730-Viscosity-Carbopol-in-Aqueous-Systems.pdf) *
NMP. MSDS for N-methylpyrrolidone. (http://www3.imperial.ac.uk/pls/portallive/docs/1/7276131.PDF) May 2001. *
Pathan, I.B.; Setty, C.M. "Chemical Penetration Enhancers for Transdermal Drug Delivery Systems" Trop. J. Pharm. Res. 2009, 8 (2), 173-179 *
Pathan, I.B.; Setty, C.M. "Chemical Penetration Enhancers for Transdermal Drug Delivery Systems" Trop. J. Pharm. Res. 2009, 8 (2), 173-179. *
Paudel, K.S. et al. "Challenges and opportunities in dermal/transdermal delivery" Ther. Deliv. July 2010, 1 (1), 109-131 *
Paudel, K.S. et al. "Challenges and opportunities in dermal/transdermal delivery" Ther. Deliv. July 2010, 1 (1), 109-131. *
Trommer, H. et al. "Overcoming the Stratum Corneum: The Modulation of Skin Penetration" Skin Pharmacol Physiol 2006;19:106–121 *
Trommer, H. et al. "Overcoming the Stratum Corneum: The Modulation of Skin Penetration" Skin Pharmacol Physiol 2006;19:106–121 *
UNC. "The Pharmaceutics and Compounding Laboratory" (http://pharmlabs.unc.edu/labs/gels/agents.htm) accessed 5 August 2014 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172344A1 (en) * 2013-04-16 2014-10-23 Alpha To Omega Pharmaceutical Consultants, Inc. Pharmaceutical compositions
EP3233077A1 (en) 2014-12-19 2017-10-25 The Broad Institute Inc. Dopamine d2 receptor ligands
US9913840B2 (en) 2015-06-08 2018-03-13 Corium International, Inc. Formulations for aripiprazole delivery transdermally

Also Published As

Publication number Publication date
JP5966228B2 (en) 2016-08-10
WO2012058091A3 (en) 2013-10-17
US20130209552A1 (en) 2013-08-15
CN107929239A (en) 2018-04-20
EP2632463B1 (en) 2018-04-04
RU2589689C2 (en) 2016-07-10
CN107929239B (en) 2021-06-01
CN103491961A (en) 2014-01-01
BR112013010190A2 (en) 2016-09-13
US9138402B2 (en) 2015-09-22
BR112013010190B1 (en) 2019-12-31
MX2013004693A (en) 2013-11-01
AU2011320758B2 (en) 2015-09-24
CA2816203A1 (en) 2012-05-03
WO2012058091A2 (en) 2012-05-03
JP2014503479A (en) 2014-02-13
CA2816203C (en) 2017-02-21
EP2632463A2 (en) 2013-09-04
RU2013124401A (en) 2014-12-10
JP2016164204A (en) 2016-09-08
CN103491961B (en) 2018-01-02
ES2675913T3 (en) 2018-07-13
AU2011320758A1 (en) 2013-05-09
EP2632463A4 (en) 2016-04-20
MX339196B (en) 2016-05-16

Similar Documents

Publication Publication Date Title
US9138402B2 (en) Aripiprazole compositions and methods for its transdermal delivery
Almeida et al. Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): Main features and their applications in topical and transdermal administration of drugs
KR102681877B1 (en) Pharmaceutical compositions of roflumilast in aqueous mixtures of water-miscible, pharmaceutically acceptable solvents
JP2017523142A5 (en)
ES2310687T3 (en) SOLID PHARMACEUTICAL DISPERSIONS OF MODAFINILO COMPOUNDS.
ES2436193T3 (en) Composition comprising an antibiotic and mometasone
WO2011049058A1 (en) Water-based paste containing diclofenac sodium
US20030211145A1 (en) Ibuprofen containing hard shell capsules
JPH10139661A (en) New therapeutic antiinflammatory and analgesic pharmaceutical composition and its production
CN1286529C (en) Skin targeting medicinal composition and its preparation and use
CN107753419B (en) Tacrolimus external preparation
US20240207206A1 (en) Improved Topical Composition of Colchicine
US9757374B2 (en) Aripiprazole compositions and methods for its transdermal delivery
JP2011102260A (en) Tacrolimus external preparation
US11400048B2 (en) Pharmaceutical oil-in-water nano-emulsion
CN104367566A (en) Indomethacin cataplasm and composition thereof
ITMI972365A1 (en) COMPOSITION BASED ON TIAMFENICOLO AND DICLOFENAC
WO2017025912A1 (en) Aripiprazole compositions and methods for its transdermal delivery
US10179138B2 (en) Pharmaceutical composition comprising 7β-hydroxycholesterol intravenous administration
EP2934524B1 (en) Penethamate veterinary injectable formulations
JPWO2010050423A1 (en) Ondansetron-containing external pharmaceutical composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC., N

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLAKOGIANNIS, FOTIOS;HOSSAIN, MUHAMMED ANWAR;SIGNING DATES FROM 20101029 TO 20101105;REEL/FRAME:030124/0610

AS Assignment

Owner name: TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC, NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC.;REEL/FRAME:035894/0504

Effective date: 20130411

AS Assignment

Owner name: TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC., NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC.;REEL/FRAME:038264/0650

Effective date: 20130411

AS Assignment

Owner name: AEQUUS PHARMACEUTICALS, INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC.;REEL/FRAME:038284/0635

Effective date: 20160301

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION